Adult: As 0.05% oint/cream: Apply thinly and rub gently onto the affected area once daily or bid, gradually discontinued once control is achieved. Max duration of therapy: 4 wk. Child: Same as adult dose. Max duration of therapy: 7 days.
Avoid contact w/ the face, eyes, scalp, genitals, groin, axilla, or between toes. Avoid use w/ occlusive dressing. Avoid abrupt withdrawal.
Monitor for adrenal insufficiency and hypothalamic-pituitary-adrenal (HPA) axis suppression.
Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplastic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasirox.
Description: Clobetasone is a glucocorticoid w/ anti-inflammatory, antipruritic, and vasoconstrictive effects. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, kinins). Additionally, it decreases the density of mast cells, chemotaxis, and cytokine production. Pharmacokinetics: Absorption: May be systemically absorbed from intact healthy skin. Metabolism: Metabolised in the liver. Excretion: Via urine and faeces.